Bimzelx (bimekizumab-bkzx) — Highmark
Ankylosing Spondylitis (AS)
Initial criteria
- age ≥ 18 years
- diagnosis of ankylosing spondylitis (AS)
- prescribed by or in consultation with a rheumatologist
- therapeutic failure or intolerance to at least one step 1 plan-preferred agent for AS
Reauthorization criteria
- disease stability or beneficial response to therapy